Chemotherapy and the war on cancer

@article{Chabner2005ChemotherapyAT,
  title={Chemotherapy and the war on cancer},
  author={B. Chabner and T. G. Roberts},
  journal={Nature Reviews Cancer},
  year={2005},
  volume={5},
  pages={65-72}
}
The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and antifolate drugs. Cancer drug development since then has transformed from a low-budget, government-supported research effort to a high-stakes, multi-billion dollar industry. The targeted-therapy revolution has arrived, but the principles and limitations of chemotherapy discovered by the early researchers still apply. This article chronicles the history of modern chemotherapy and identifies remaining… Expand
Cancer chemotherapy: an annotated history.
  • W. Morrison
  • Medicine
  • Journal of veterinary internal medicine
  • 2010
TLDR
Human and veterinary cancer chemotherapy have coevolved in the context of fascinating historical, political, and scientific events created by equally fascinating individuals. Expand
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
TLDR
Today, cancer research is always aimed at the study and development of new therapeutic approaches for cancer treatment, and several researchers are focused on the development of cell therapies, anti-tumor vaccines, and new biotechnological drugs that have already shown promising results in preclinical studies, therefore, in the near future, it will certainly assist to a new revolution in the field of medical oncology. Expand
Standing in the Shifting Sands of Molecular Targeting and Precision Medicine Is the Oasis of 21st‐Century Oncology Therapeutics
TLDR
Oncology-themed supplement provides a collection of expert scientific updates in clinical oncology therapeutics and highlights key areas in which the discipline of clinical pharmacology has played a prominent role. Expand
Cancer chemotherapy: a critical analysis of its 60 years of history.
TLDR
The current results of old or new agents can only be improved by understanding the natural history of each specific cancer subtype at the clinical level and by overcoming the physiological barriers involved in chemotherapy failure, which will surely allow to enlarge the list of curable cancers by chemotherapy. Expand
Genomics and the second golden era of cancer drug development.
The first golden era of cancer drug development was initiated in the 1940s and gave rise to the cytotoxic agents that dominate current cancer medicine. The second golden era is now underway in whichExpand
Systemic cancer therapy: Evolution over the last 60 years
The 1940s marked the beginning of an era of important discoveries that contributed to modern concepts underlying the current practice of cancer chemotherapy, such as the log kill hypothesis reportedExpand
Chemotherapy over the Years
At the beginning of the 20th century, attempts to use chemotherapy for the treatment of cancer were started, and the first four decades of the 20th century were mainly dedicated to model development.Expand
Understanding resistance to combination chemotherapy.
TLDR
It is suggested that emerging systems/network biology approaches have an immense opportunity to impact the rational development of successful drug regimens by examining drug combinations in multivariate ways, so that next generation combination therapies can be constructed with a clear understanding of how mechanisms of resistance to multi-drug regimens differ from single agent resistance. Expand
Drug Development Against Metastatic Cancers
TLDR
The evolution of past and current anti-cancer drug development, the limits of current strategies, and possible alternative approaches for future drug development against metastatic cancers are discussed. Expand
Search for new and novel chemotherapeutics for the treatment of human malignancies.
TLDR
In this review, glimpses on types of current chemotherapeutic agents based on their action of inhibition and the new molecules that are being developed based on the scaffolds across the world as well as in this laboratory have been articulated. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 94 REFERENCES
Origins of cancer therapy.
  • R. Papac
  • Medicine
  • The Yale journal of biology and medicine
  • 2001
TLDR
The modern era of chemotherapy developed at Yale University Medical School during World War II, a fact that has been generally unrecognized until recently. Expand
The national program for cancer chemotherapy.
TLDR
Establishment and calibration of the appropriate models took ten years, and based on these correlations, in 1965 NCI instituted its present operation of drug development, and since 1965, NCI has refined this empiric blueprint as dictated by experience and new data. Expand
The National Cancer Chemotherapy Program.
TLDR
The National Cancer Chemotherapy Program was initiated in 1955 and has increasingly emphasized and been influenced by advances in tumor biology, drug development, clinical pharmacology, and the science of clinical trials. Expand
The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug
Acknowledgements Abbreviations Introduction Part I. Agents: 1. Cancer chemotherapy: plant knowledge and practice Part II. Practices: 2. Act I: 1962-75 3. Act II: 1976-83 4. Act III: 1984-9 Part III.Expand
The pharmacology and clinical use of methotrexate.
METHOTREXATE, the most widely used antimetabolite in cancer chemotherapy, has an essential role in the treatment of such diverse diseases as acute lymphocytic leukemia, non-Hodgkin's lymphoma, oste...
Intrinsic and acquired resistance to methotrexate in acute leukemia.
Methotrexate, a folic acid antagonist, is used extensively not only for the treatment of cancer but also for the treatment of rheumatoid arthritis, psoriasis, and autoimmune disease and for theExpand
Intensive combination chemotherapy and X-irradiation in Hodgkin's disease.
TLDR
It appears that the incidence of complete remissions can be increased over that obtained with a single agent and the duration of complete unmaintained remission in those patients with advanced disease is provocative even though the group is small. Expand
There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.
TLDR
An appreciation that both bench and clinical investigations are difficult endeavors should aid in improving clinical trial designs and give the best chance for new agents to be added to the therapeutic armamentarium. Expand
Anticancer drug development at the US National Cancer Institute
  • C. Takimoto
  • Medicine
  • Cancer Chemotherapy and Pharmacology
  • 2003
TLDR
This review summarizes the history of drug screening and development efforts at the NCI over the past five decades from its inception up to its current state emphasizing molecularly targeted therapies. Expand
The National Cancer Institute: cancer drug discovery and development program.
TLDR
An update on the NCI's revised cancer screen is accompanied by a brief summary of those new agents scheduled to be entered into clinical investigation in the near future. Expand
...
1
2
3
4
5
...